Liver Cirrhosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Liver Cirrhosis Market is Segmented By Etiology (Alcoholic Liver Cirrhosis, Nonalcoholic Fatty Liver Disease (NAFLD), Viral Hepatitis, Other Causes), By Treatment (Medication, Ursodeoxycholic Acid (UDCA), Corticosteroids, Antiviral Drugs, Liver Transplantation, Supportive Care), By Disease Stage (Compensated Cirrhosis, Decompensated Cirrhosis), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic & Research Institutes, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Liver Cirrhosis Market Size
Market Size in USD
CAGR5.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5.2% |
| Market Concentration | High |
| Major Players | Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, CymaBay Therapeutics, Akero Therapeutics, Inc. |
please let us know !
Liver Cirrhosis Market Analysis
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031. The increasing prevalence of liver diseases and rising alcohol consumption globally are major factors contributing to the growth of liver cirrhosis cases.
Key factors such as the rising geriatric population, growing awareness about liver cirrhosis treatment and management, new product approvals, and improving healthcare infrastructure in developing nations are expected to contribute to the market growth during the forecast period. However, the high cost of treatment and lack of effective diagnosis and treatment in developing countries are some challenges restraining the market growth.